Lenalidomide and cyclophosphamide immunoregulation in patients with metastatic, castration-resistant prostate cancer

Clinical and Experimental Metastasis

Volumn 32, Issue 2, 2015, Pages 111-124

  Wang, J ^a,c   McGuire, T R ^a   Britton, H C ^a   Schwarz, J K ^a   Loberiza, F R ^a   Meza, J L ^b   Talmadge, J E ^a  

^a NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

Author keywords

Circulating tumor cells; FoxP3+ T regulatory (T reg) cell; Lenalidomide; Metastatic castration resistant prostate cancer; Metronomic chemotherapy; Myeloid derived suppressor cell

Indexed keywords

ACETYLSALICYLIC ACID; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CREATININE; CYCLOPHOSPHAMIDE; DOCETAXEL; INTERLEUKIN 6; INTERLEUKIN 8; LENALIDOMIDE; PROSTATE SPECIFIC ANTIGEN; ANTINEOPLASTIC AGENT; CYTOKINE; IMMUNOSUPPRESSIVE AGENT; THALIDOMIDE;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; B LYMPHOCYTE; BACKACHE; CANCER COMBINATION CHEMOTHERAPY; CANCER FATIGUE; CANCER PATIENT; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED EMESIS; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONSTIPATION; CONTROLLED STUDY; COUGHING; CREATININE BLOOD LEVEL; DEHYDRATION; DIARRHEA; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DYSGEUSIA; DYSPNEA; EDEMA; FEBRILE NEUTROPENIA; HUMAN; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; HYPOTENSION; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; LEG PAIN; LOWER RESPIRATORY TRACT INFECTION; LUNG EMBOLISM; LYMPHOCYTOPENIA; MALE; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NATURAL KILLER CELL; NAUSEA; OPEN STUDY; PATIENT SAFETY; PHASE 2 CLINICAL TRIAL; PROTEIN BLOOD LEVEL; SIDE EFFECT; T LYMPHOCYTE; THORAX PAIN; THROMBOCYTOPENIA; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; VENOUS THROMBOEMBOLISM; ANALOGS AND DERIVATIVES; BONE MARROW CELL; CLINICAL TRIAL; CYTOLOGY; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; IMMUNOLOGY; KAPLAN MEIER METHOD; LEUKOCYTE; METABOLISM; MIDDLE AGED; PHASE 1 CLINICAL TRIAL; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TIME; TREATMENT OUTCOME; TUMOR EMBOLISM; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CYCLOPHOSPHAMIDE; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIER ESTIMATE; LEUKOCYTES; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MYELOID CELLS; NEOPLASTIC CELLS, CIRCULATING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; THALIDOMIDE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84925486782     PISSN: 02620898     EISSN: 15737276     Source Type: Journal    
DOI: 10.1007/s10585-015-9696-3     Document Type: Article

References (64)

1. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363(5):411–422. doi:10.1056/NEJMoa1001294
2. Jochems C, Tucker JA, Tsang KY, Madan RA, Dahut WL, Liewehr DJ, Steinberg SM, Gulley JL, Schlom J (2014) A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates. Cancer Immunol Immunother 63(4):407–418. doi:10.1007/s00262-014-1524-0
3. Xu J, Escamilla J, Mok S, David J, Priceman S, West B, Bollag G, McBride W, Wu L (2013) CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer. Cancer Res 73(9):2782–2794. doi:10.1158/0008-5472.CAN-12-3981
4. Sorrentino C, Musiani P, Pompa P, Cipollone G, Di Carlo E (2011) Androgen deprivation boosts prostatic infiltration of cytotoxic and regulatory T lymphocytes and has no effect on disease-free survival in prostate cancer patients. Clin Cancer Res 17(6):1571–1581. doi:10.1158/1078-0432.ccr-10-2804
5. Talmadge JE, Gabrilovich DI (2013) History of myeloid-derived suppressor cells. Nat Rev Cancer 13(10):739–752. doi:10.1038/nrc3581
6. Vuk-Pavlovic S, Bulur PA, Lin Y, Qin R, Szumlanski CL, Zhao X, Dietz AB (2010) Immunosuppressive CD14+HLA-DRlow/-monocytes in prostate cancer. Prostate 70(4):443–455. doi:10.1002/pros.21078
7. Berd D, Mastrangelo MJ (1988) Effect of low dose cyclophosphamide on the immune system of cancer patients: depletion of CD4+, 2H4+ suppressor-inducer T-cells. Cancer Res 48(6):1671–1675
8. Nabhan C, Patel A, Villines D, Tolzien K, Kelby SK, Lestingi TM (2014) Lenalidomide monotherapy in chemotherapy-naive, castration-resistant prostate cancer patients: final results of a phase II study. Clin Genitourin Cancer 12(1):27–32. doi:10.1016/j.clgc.2013.09.001
9. Dahut WL, Aragon-Ching JB, Woo S, Tohnya TM, Gulley JL, Arlen PM, Wright JJ, Ventiz J, Figg WD (2009) Phase I study of oral lenalidomide in patients with refractory metastatic cancer. J Clin Pharmacol 49(6):650–660. doi:10.1177/0091270009335001
10. Garcia JA, Elson P, Tyler A, Triozzi P, Dreicer R (2014) Sargramostim (GM-CSF) and lenalidomide in castration-resistant prostate cancer (CRPC): results from a phase I-II clinical trial. Urol Oncol 32(1):33 e11–33 e37. doi:10.1016/j.urolonc.2012.12.004
11. Ehrke MJ, Mihich E, Berd D, Mastrangelo MJ (1989) Effects of anticancer drugs on the immune system in humans. Semin Oncol 16(3):230–253
12. Busch A, Zeh D, Janzen V, Mugge LO, Wolf D, Fingerhut L, Hahn-Ast C, Maurer O, Brossart P, von Lilienfeld-Toal M (2014) Treatment with lenalidomide induces immunoactivating and counter-regulatory immunosuppressive changes in myeloma patients. Clin Exp Immunol. doi:10.1111/cei.12343
13. Gorgun GT, Whitehill G, Anderson JL, Hideshima T, Maguire C, Laubach J, Raje N, Munshi NC, Richardson PG, Anderson KC (2013) Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans. Blood 121(15):2975–2987. doi:10.1182/blood-2012-08-448548
14. Sakamaki I, Kwak LW, Cha SC, Yi Q, Lerman B, Chen J, Surapaneni S, Bateman S, Qin H (2014) Lenalidomide enhances the protective effect of a therapeutic vaccine and reverses immune suppression in mice bearing established lymphomas. Leukemia 28(2):329–337. doi:10.1038/leu.2013.177
15. Pal R, Monaghan SA, Hassett AC, Mapara MY, Schafer P, Roodman GD, Ragni MV, Moscinski L, List A, Lentzsch S (2010) Immunomodulatory derivatives induce PU. 1 down-regulation, myeloid maturation arrest, and neutropenia. Blood 115(3):605–614. doi:10.1182/blood-2009-05-221077
16. Devaud C, John LB, Westwood JA, Darcy PK, Kershaw MH (2013) Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy. Oncoimmunology 2(8):e25961. doi:10.4161/onci.25961
17. Abbas AK, Benoist C, Bluestone JA, Campbell DJ, Ghosh S, Hori S, Jiang S, Kuchroo VK, Mathis D, Roncarolo MG, Rudensky A, Sakaguchi S, Shevach EM, Vignali DAA, Ziegler SF (2013) Regulatory T cells: recommendations to simplify the nomenclature. Nat Immunol 14(4):307–308
18. Arlen PM, Bianco F, Dahut WL, D’Amico A, Figg WD, Freedland SJ, Gulley JL, Kantoff PW, Kattan MW, Lee A, Regan MM, Sartor O, Prostate Specific Antigen Working G (2008) Prostate specific antigen working group guidelines on prostate specific antigen doubling time. J Urol 179(6):2181–2185. doi:10.1016/j.juro.2008.01.099 discussion 2185-2186
19. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247. doi:10.1016/j.ejca.2008.10.026
20. Riethdorf S, Fritsche H, Muller V, Rau T, Schindlbeck C, Rack B, Janni W, Coith C, Beck K, Janicke F, Jackson S, Gornet T, Cristofanilli M, Pantel K (2007) Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the cell search system. Clin Cancer Res 13(3):920–928. doi:10.1158/1078-0432.CCR-06-1695
21. Scher H, Heller G, Molina A, Kheoh T, Attard G, Moreira J et al (2011) Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): planned final analysis (FA) of COU-AA-301, a randomized, double-blind, placebo-controlled, phase III study of abiraterone acetate (AA) plus low-dose prednisone (P) post docetaxel. Paper presented at the ASCO meeting abstracts
22. de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, Doyle GV, Terstappen LW, Pienta KJ, Raghavan D (2008) Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 14(19):6302–6309. doi:10.1158/1078-0432.ccr-08-0872
23. Mills KC, Gross TG, Varney ML, Heimann DG, Reed EC, Kessinger A, Talmadge JE (1996) Immunologic phenotype and function in human bone marrow, blood stem cells and umbilical cord blood. Bone Marrow Transpl 18(1):53–61
24. Talmadge JE, Reed EC, Kessinger A, Kuszynski CA, Perry GA, Gordy CL, Mills KC, Thomas ML, Pirruccello SJ, Letheby BA, Arneson MA, Jackson JD (1996) Immunologic attributes of cytokine mobilized peripheral blood stem cells and recovery following transplantation. Bone Marrow Transpl 17(1):101–109
25. Singh RK, Varney ML, Buyukberber S, Ino K, Ageitos AG, Reed E, Tarantolo S, Talmadge JE (1999) Fas-FasL-mediated CD4+ T-cell apoptosis following stem cell transplantation. Cancer Res 59(13):3107–3111
26. Singh RK, Ino K, Varney ML, Heimann DG, Talmadge JE (1999) Immunoregulatory cytokines in bone marrow and peripheral blood stem cell products. Bone Marrow Transpl 23(1):53–62
27. Talmadge JE, Reed E, Ino K, Kessinger A, Kuszynski C, Heimann D, Varney M, Jackson J, Vose JM, Bierman PJ (1997) Rapid immunologic reconstitution following transplantation with mobilized peripheral blood stem cells as compared to bone marrow. Bone Marrow Transpl 19(2):161–172
28. Varney M, Ino K, Ageitos A, Heimann D, Talmadge J, Singh R (1999) Expression of interleukin-10 in isolated CD8(+) T cells and monocytes from growth factor-mobilized peripheral blood stem cell products: a mechanism of immune dysfunction. J Interferon Cytokine Res 19(4):351–360
29. Ino K, Singh RK, Talmadge JE (1997) Monocytes from mobilized stem cells inhibit T cell function. J Leukoc Biol 61(5):583–591
30. Singh RK, Varney ML, Leutzinger C, Vose JM, Bierman PJ, Buyukberber S, Ino K, Loh K, Nichols C, Inwards D, Rifkin R, Talmadge JE (2007) Immune reconstitution after autologous hematopoietic transplantation with Lin−, CD34+, Thy-1lo selected or intact stem cell products. Int Immunopharmacol 7(8):1033–1043. doi:10.1016/j.intimp.2007.03.006
31. Sharma J, Gray KP, Harshman LC, Evan C, Nakabayashi M, Fichorova R, Rider J, Mucci L, Kantoff PW, Sweeney CJ (2014) Elevated IL-8, TNF-alpha, and MCP-1 in men with metastatic prostate cancer starting androgen-deprivation therapy (ADT) are associated with shorter time to castration-resistance and overall survival. Prostate 74(8):820–828. doi:10.1002/pros.22788
32. Nguyen DP, Li J, Tewari AK (2013) Inflammation and prostate cancer: the role of interleukin-6. BJU Int. doi:10.1111/bju.12452
33. Donkor MK, Lahue E, Hoke TA, Shafer LR, Coskun U, Solheim JC, Gulen D, Bishay J, Talmadge JE (2009) Mammary tumor heterogeneity in the expansion of myeloid-derived suppressor cells. Int Immunopharmacol 9(7–8):937–948. doi:10.1016/j.intimp.2009.03.021
34. Rashid OM, Nagahashi M, Ramachandran S, Graham L, Yamada A, Spiegel S, Bear HD, Takabe K (2013) Resection of the primary tumor improves survival in metastatic breast cancer by reducing overall tumor burden. Surgery. doi:10.1016/j.surg.2013.02.002
35. Younos IH, Dafferner AJ, Gulen D, Britton HC, Talmadge JE (2012) Tumor regulation of myeloid-derived suppressor cell proliferation and trafficking. Int Immunopharmacol 13(3):245–256. doi:10.1016/j.intimp.2012.05.002
36. Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ (2009) Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol 58(1):49–59. doi:10.1007/s00262-008-0523-4
37. Porembka M, Mitchem J, Belt B, Hsieh C, Lee H, Herndon J, Gillanders W, Linehan D, Goedegebuure P (2012) Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth. Cancer Immunol Immunother 61:1373–1385
38. Monroe JG, Dorshkind K (2007) Fate decisions regulating bone marrow and peripheral B lymphocyte development. Adv Immunol 95:1–50. doi:10.1016/S0065-2776(07)95001-4
39. Beer TM, Ryan CW, Venner PM, Petrylak DP, Chatta GS, Ruether JD, Redfern CH, Fehrenbacher L, Saleh MN, Waterhouse DM, Carducci MA, Vicario D, Dreicer R, Higano CS, Ahmann FR, Chi KN, Henner WD, Arroyo A, Clow FW, Investigators A (2007) Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT investigators. J Clin Oncol 25(6):669–674. doi:10.1200/JCO.2006.06.8197
40. Lin YC, Wu SC (2006) Effects of ozone exposure on inactivation of intra- and extracellular enterovirus 71. Antivir Res 70(3):147–153
41. Lukito W, Wattanapenpaiboon N, Savige GS, Hutchinson P, Wahlqvist ML (2004) Nutritional indicators, peripheral blood lymphocyte subsets and survival in an institutionalised elderly population. Asia Pac J Clin Nutr 13(1):107–112
42. Shaffer DR, Leversha MA, Danila DC, Lin O, Gonzalez-Espinoza R, Gu B, Anand A, Smith K, Maslak P, Doyle GV, Terstappen LW, Lilja H, Heller G, Fleisher M, Scher HI (2007) Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin Cancer Res 13(7):2023–2029. doi:10.1158/1078-0432.CCR-06-2701
43. Rashid OM, Nagahashi M, Ramachandran S, Graham L, Yamada A, Spiegel S, Bear HD, Takabe K (2013) Resection of the primary tumor improves survival in metastatic breast cancer by reducing overall tumor burden. Surgery 153(6):771–778. doi:10.1016/j.surg.2013.02.002
44. Ademokun A, Wu YC, Dunn-Walters D (2010) The ageing B cell population: composition and function. Biogerontology 11(2):125–137. doi:10.1007/s10522-009-9256-9
45. Wikby A, Johansson B, Ferguson F, Olsson J (1994) Age-related changes in immune parameters in a very old population of Swedish people: a longitudinal study. Exp Gerontol 29(5):531–541
46. Paganelli R, Quinti I, Fagiolo U, Cossarizza A, Ortolani C, Guerra E, Sansoni P, Pucillo LP, Scala E, Cozzi E et al (1992) Changes in circulating B cells and immunoglobulin classes and subclasses in a healthy aged population. Clin Exp Immunol 90(2):351–354
47. Thorn M, Point GR, Burga RA, Nguyen CT, Espat NJ, Katz SC (2014) Liver metastases induce reversible hepatic B cell dysfunction mediated by Gr-1+ CD11b+ myeloid cells. J Leukoc Biol 96(5):883–894. doi:10.1189/jlb.3A0114-012RR
48. Green KA, Cook WJ, Green WR (2013) Myeloid-derived suppressor cells in murine retrovirus-induced AIDS inhibit T- and B-cell responses in vitro that are used to define the immunodeficiency. J Virol 87(4):2058–2071. doi:10.1128/JVI.01547-12
49. Mikyskova R, Indrova M, Vlkova V, Bieblova J, Simova J, Parackova Z, Pajtasz-Piasecka E, Rossowska J, Reinis M (2014) DNA demethylating agent 5-azacytidine inhibits myeloid-derived suppressor cells induced by tumor growth and cyclophosphamide treatment. J Leukoc Biol. doi:10.1189/jlb.0813435
50. Mikyskova R, Indrova M, Pollakova V, Bieblova J, Simova J, Reinis M (2012) Cyclophosphamide-induced myeloid-derived suppressor cell population is immunosuppressive but not identical to myeloid-derived suppressor cells induced by growing TC-1 tumors. J Immunother 35(5):374–384. doi:10.1097/CJI.0b013e318255585a
51. Medina-Echeverz J, Fioravanti J, Zabala M, Ardaiz N, Prieto J, Berraondo P (2011) Successful colon cancer eradication after chemoimmunotherapy is associated with profound phenotypic change of intratumoral myeloid cells. J Immunol 186(2):807–815. doi:10.4049/jimmunol.1001483
52. Sevko A, Sade-Feldman M, Kanterman J, Michels T, Falk CS, Umansky L, Ramacher M, Kato M, Schadendorf D, Baniyash M, Umansky V (2013) Cyclophosphamide promotes chronic inflammation-dependent immunosuppression and prevents antitumor response in melanoma. J Investig Dermatol 133(6):1610–1619. doi:10.1038/jid.2012.444
53. Galustian C, Meyer B, Labarthe MC, Dredge K, Klaschka D, Henry J, Todryk S, Chen R, Muller G, Stirling D, Schafer P, Bartlett JB, Dalgleish AG (2009) The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother 58(7):1033–1045. doi:10.1007/s00262-008-0620-4
54. Giannopoulos K, Dmoszynska A, Kowal M, Wasik-Szczepanek E, Bojarska-Junak A, Rolinski J, Dohner H, Stilgenbauer S, Bullinger L (2009) Thalidomide exerts distinct molecular antileukemic effects and combined thalidomide/fludarabine therapy is clinically effective in high-risk chronic lymphocytic leukemia. Leukemia 23(10):1771–1778. doi:10.1038/leu.2009.98
55. Salem ML, Al-Khami AA, El-Nagaar SA, Zidan AA, Al-Sharkawi IM, Marcela Diaz-Montero C, Cole DJ (2012) Kinetics of rebounding of lymphoid and myeloid cells in mouse peripheral blood, spleen and bone marrow after treatment with cyclophosphamide. Cell Immunol 276(1–2):67–74. doi:10.1016/j.cellimm.2012.03.010
56. Barbon CM, Yang M, Wands GD, Ramesh R, Slusher BS, Hedley ML, Luby TM (2010) Consecutive low doses of cyclophosphamide preferentially target T regs and potentiate T cell responses induced by DNA PLG microparticle immunization. Cell Immunol 262(2):150–161. doi:10.1016/j.cellimm.2010.02.007
57. Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, Szczylik C, Staehler M, Brugger W, Dietrich PY, Mendrzyk R, Hilf N, Schoor O, Fritsche J, Mahr A, Maurer D, Vass V, Trautwein C, Lewandrowski P, Flohr C, Pohla H, Stanczak JJ, Bronte V, Mandruzzato S, Biedermann T, Pawelec G, Derhovanessian E, Yamagishi H, Miki T, Hongo F, Takaha N, Hirakawa K, Tanaka H, Stevanovic S, Frisch J, Mayer-Mokler A, Kirner A, Rammensee HG, Reinhardt C, Singh-Jasuja H (2012) Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 18(8):1254–1261. doi:10.1038/nm.2883
58. Berd D, Maguire HC Jr, Mastrangelo MJ (1986) Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide. Cancer Res 46(5):2572–2577
59. Drachenberg DE, Elgamal AA, Rowbotham R, Peterson M, Murphy GP (1999) Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer. Prostate 41(2):127–133
60. Smith PC, Hobisch A, Lin DL, Culig Z, Keller ET (2001) Interleukin-6 and prostate cancer progression. Cytokine Growth Factor Rev 12(1):33–40
61. Lou W, Ni Z, Dyer K, Tweardy DJ, Gao AC (2000) Interleukin-6 induces prostate cancer cell growth accompanied by activation of stat3 signaling pathway. Prostate 42(3):239–242
62. Adler HL, McCurdy MA, Kattan MW, Timme TL, Scardino PT, Thompson TC (1999) Elevated levels of circulating interleukin-6 and transforming growth factor-beta 1 in patients with metastatic prostatic carcinoma. J Urol 161(1):182–187
63. Qu Y, Oyan AM, Liu R, Hua Y, Zhang J, Hovland R, Popa M, Liu X, Brokstad KA, Simon R, Molven A, Lin B, Zhang WD, McCormack E, Kalland KH, Ke XS (2013) Generation of prostate tumor-initiating cells is associated with elevation of reactive oxygen species and IL-6/STAT3 signaling. Cancer Res 73(23):7090–7100. doi:10.1158/0008-5472.can-13-1560
64. Lehrer S, Diamond EJ, Mamkine B, Stone NN, Stock RG (2004) Serum interleukin-8 is elevated in men with prostate cancer and bone metastases. Technol Cancer Res Treat 3(5):411